Anti-obesity drug discovery: advances and challenges
Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …
[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …
type 2 diabetes in 2005 have been further developed to yield effective compounds …
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
[HTML][HTML] Semaglutide lowers body weight in rodents via distributed neural pathways
Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers
glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic …
glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic …
[HTML][HTML] Anxiety, depression, and the microbiome: a role for gut peptides
The complex bidirectional communication between the gut and the brain is finely
orchestrated by different systems, including the endocrine, immune, autonomic, and enteric …
orchestrated by different systems, including the endocrine, immune, autonomic, and enteric …
Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB
The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …
management of obesity and type 2 diabetes mellitus and novel developments in …
GLP− 1 receptor agonists for the treatment of obesity: Role as a promising approach
JY Wang, QW Wang, XY Yang, W Yang… - Frontiers in …, 2023 - frontiersin.org
Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …
by genetic, environmental and other factors. In recent years, there has been an increase in …
Obesity and addiction: neurobiological overlaps
Drug addiction and obesity appear to share several properties. Both can be defined as
disorders in which the saliency of a specific type of reward (food or drug) becomes …
disorders in which the saliency of a specific type of reward (food or drug) becomes …
Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
Aim The aim of this trial was to investigate the mechanism of action for body weight loss with
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …
[HTML][HTML] “Eating addiction”, rather than “food addiction”, better captures addictive-like eating behavior
Abstract “Food addiction” has become a focus of interest for researchers attempting to
explain certain processes and/or behaviors that may contribute to the development of …
explain certain processes and/or behaviors that may contribute to the development of …